Deal parties are planning for scrutiny from merger reviews to employee activism. Are there methods for 'testing the waters' with antitrust regulators before agreeing to a deal?

If there is potential for a long regulatory review, what deal terms should flex?

How are interim operating covenants being designed to avoid gun jumping?

What is the current market for efforts to close and break fees if the resistance is too strong?

Michael Wolf, Vice President, Deputy General Counsel, Baxter International
Cassie Chong, Senior Vice President, Associate General Counsel, Transactions, Bristol Myers Squibb
Chair: Ben Gris, Partner, Antitrust Practice, Shearman & Sterling

Sorry, there are no results for your search. Please try again.